Market Overview - On February 6, the A-share market experienced significant volatility, with the three major indices initially rebounding after a low open, but ultimately closing lower. The Shanghai Composite Index fell by 0.25% to 4065.58 points, the Shenzhen Component Index decreased by 0.33% to 13906.73 points, and the ChiNext Index dropped by 0.73% to 3236.46 points. The total market turnover was 2.16 trillion yuan, a decrease of 30.8 billion yuan from the previous trading day, with over 2700 stocks rising [1]. Sector Performance Strong Performing Sectors - The mining and oil sectors saw gains, with stocks like Tongyuan Petroleum and Zhun Oil Co. hitting the daily limit [1]. - The chemical sector, particularly fluorine chemicals, showed strength, with Tianji Co. reaching the daily limit. Lithium mining and battery sectors were also active, with stocks such as Kosen Technology and Dingsheng New Materials hitting the daily limit [1]. - The traditional Chinese medicine sector led the market, with stocks like Te Yi Pharmaceutical and Hansen Pharmaceutical hitting the daily limit, supported by a new development plan from the Ministry of Industry and Information Technology [2]. - The chemical sector experienced a collective surge, driven by rising prices of disperse dyes due to increased costs of upstream intermediates [2]. - The power equipment sector rebounded, with stocks like Jinkong Electric and Sanbian Technology hitting the daily limit, reflecting strong demand in the electricity industry [2]. Weak Performing Sectors - The consumer sector, including liquor, tourism, and retail, faced a collective decline, with stocks like Huangtai Liquor hitting the daily limit down [4]. - Real estate-related concepts declined, with Jingtou Development falling over 5%, amid mixed expectations for industry recovery [5]. - AI application concepts saw a downturn, with various AI-related stocks experiencing declines due to uncertainties in commercialization [6]. - The "中字头" (state-owned enterprises) and financial sectors also retreated, as investors sought safer investment strategies following previous gains [6]. Institutional Insights - CICC remains optimistic about the revaluation of Chinese assets, noting that there are no typical signs of a market top despite external pressures. The firm suggests maintaining an overweight position in Chinese stocks and looking for buying opportunities during market fluctuations [7]. - Tianfeng Securities highlights that market sentiment is fragile, with short-term investors cashing out as a primary reason for recent declines in gold prices. They anticipate a period of volatility for gold but expect it to rebound later in the year [7]. - Huachuang Securities predicts a strong recovery in the consumption market during the 2026 Spring Festival, driven by government-led initiatives and diverse promotional activities, which may exceed market expectations [8].

Market Overview - The market showed a recovery after an initial drop, with all three major indices closing in the green. The Shanghai Composite Index rose by 0.11%, the Shenzhen Component increased by 0.65%, and the ChiNext Index also gained 0.65% [1] Sector Performance - The chemical sector performed strongly, with stocks such as Cangzhou Dahua, Jinniu Chemical, Baichuan Co., and Baihehua hitting the daily limit [2] - The humanoid robot concept saw active performance, with stocks like Wuzhou Xinchun, Liancheng Precision, and Tianqi Co. reaching the daily limit [3] - The non-ferrous metals sector rebounded, with Hunan Gold and Xianglu Tungsten hitting the daily limit. The optical communication concept also saw a recovery, with Hangdian Co. achieving five consecutive daily limits [4] - The traditional Chinese medicine concept opened actively, with Te Yi Pharmaceutical hitting the daily limit [5] - Conversely, the consumer sector faced a collective decline, particularly in the liquor and tourism hotel sectors, with Huangtai Liquor and Dalian Shengya hitting the daily limit [6] Trading Volume - The total trading volume in the Shanghai and Shenzhen markets reached 1.38 trillion yuan, a decrease of 63.3 billion yuan compared to the previous trading day [7] Individual Stock Highlights - Zhongji Xuchuang had the highest trading volume at over 11.5 billion yuan, followed closely by Xinyi Sheng at 11.3 billion yuan. Other notable stocks with high trading volumes included Ningde Times, Kweichow Moutai, Zijin Mining, and Xunwei Communication [8]

Market Overview - The US labor market data has intensified market pessimism, leading to a systematic sell-off in the tech sector, which has quickly spread globally, putting pressure on risk assets and entering a clear "de-leveraging resonance" phase [1] - The three major indices opened lower but later rebounded, with the Shanghai Composite Index rising by 0.11%, the Shenzhen Component Index by 0.65%, and the ChiNext Index by 0.65% at midday [1] - The trading volume in the Shanghai and Shenzhen markets was 1.38 trillion yuan, a decrease of 63.3 billion yuan compared to the previous trading day [1] Geopolitical Impact - The situation in Iran remains tense, with the US State Department issuing a security warning for American citizens to leave Iran and prepare for self-reliant exit plans [2] - This geopolitical tension has led to a significant rebound in precious metals, with silver rising by 8% to $72.54 per ounce and gold increasing by over 1% to $4,826.9 per ounce [2] - International oil prices have also reversed course, with Brent crude rising from $66.9 to $67.5 [2] Sector Performance Chemical Sector - The chemical sector saw a broad rally, with stocks like Jinniu Chemical and Cangzhou Dahua hitting the daily limit [3][5] - The price of key intermediate materials for disperse dyes has surged from 25,000 yuan per ton to 38,000 yuan per ton, an increase of over 50% [5] Traditional Chinese Medicine - Stocks in the traditional Chinese medicine sector surged, with companies like Te Yi Pharmaceutical and Hansen Pharmaceutical hitting the daily limit [4] - The Ministry of Industry and Information Technology has issued a development plan for the traditional Chinese medicine industry, aiming for a collaborative development system by 2030 [4] Power Equipment - The power equipment sector, including transformers, showed strong performance with stocks like Jinkong Electric and Sanbian Technology hitting the daily limit [6][7] Precious Metals - The precious metals sector has rebounded, with stocks like Hunan Gold and Xianglu Tungsten hitting the daily limit [8] - Silver prices increased by over 2% during the day, while gold prices returned above $4,800 [8] Institutional Insights - CICC maintains a positive outlook on the Chinese stock market, noting that there are no typical bull market top signals, and the funding environment remains ample with improving performance [9][10] - Tianfeng Securities highlights that market sentiment is fragile, with any news changes potentially triggering concentrated sell-offs by short-term investors [11] - Huachuang Securities anticipates a strong recovery in the consumption market during the 2026 Spring Festival, driven by government-led initiatives and diverse promotional activities [12]

中药概念集体高开，消息面上，2026年2月5日，工业和信息化部等八部门联合发布《中药工业高质量发 展实施方案（2026—2030年）》，本文件是对2025年3月《国务院办公厅 关于提升中药质量促进中医药 产业高质量发展的意见》的分解执行。文件部署了六方面任务：原料提质稳供、协同创新攻关、制造能 力提升、民族药产业振兴、卓越企业培育。到2030年，争取推动一批中药创新药获批上市，新培育10个 中成药大品种。分批次挖掘具有突出临床价值的中成药潜力品种，培育一批新的中成药大单品。依托中 国消费名品名单等载体，有序打造中药名品方阵 中药ETF紧密跟踪中证中药指数，中证中药指数选取涉及中药生产与销售等业务的上市公司证券作为样 本，以反映中药概念类上市公司的整体表现。 数据显示，截至2026年1月30日，中证中药指数(930641)前十大权重股分别为云南白药、片仔癀、东阿 阿胶、同仁堂、吉林敖东、华润三九、白云山、以岭药业、众生药业、达仁堂，前十大权重股合计占比 55.13%。 中药ETF(159647)，场外联接(A：016891；C：016892；I：022881)。 机构认为：基药目录即将出台，院内中药大单品呼之欲 ...

数据显示，截至2026年1月30日，中证中药指数(930641)前十大权重股分别为云南白药、片仔癀、东阿 阿胶、同仁堂、吉林敖东、华润三九、白云山、以岭药业、众生药业、达仁堂，前十大权重股合计占比 55.13%。 中药ETF(159647)，场外联接(A：016891；C：016892；I：022881)。 截至2026年2月5日 10:09，中证中药指数(930641)上涨0.92%，成分股达仁堂上涨3.67%，方盛制药上涨 3.62%，片仔癀上涨3.23%，华润江中上涨2.03%，广誉远上涨1.90%。中药ETF(159647)上涨0.92%， 冲 击3连涨。最新价报0.99元。 中药ETF紧密跟踪中证中药指数，中证中药指数选取涉及中药生产与销售等业务的上市公司证券作为样 本，以反映中药概念类上市公司的整体表现。 消息面上，多地政策持续支持中药产业，浙江提出培育壮大 生物医药等新兴产业，此前河南提出，培 育3—5个年营业收入超过30亿元的中药企业 建设具有全国影响力的中药产业集群。 世纪证券指出，1月27日，《中华人民共和国药品管理法实施条例》正式公布，配合2023年公布的《中 药注册管理专门规定》，确立 ...

中药ETF紧密跟踪中证中药指数，中证中药指数选取涉及中药生产与销售等业务的上市公司证券作为样 本，以反映中药概念类上市公司的整体表现。 数据显示，截至2025年11月28日，中证中药指数(930641)前十大权重股分别为云南白药(000538)、片仔 癀(600436)、同仁堂(600085)、东阿阿胶(000423)、华润三九(000999)、吉林敖东(000623)、白云山 (600332)、众生药业(002317)、以岭药业(002603)、达仁堂(600329)，前十大权重股合计占比54.79%。 中药ETF(159647)，场外联接(A：016891；C：016892；I：022881)。 截至2025年12月3日 10:13，中证中药指数(930641)上涨0.32%，成分股粤万年青(301111)上涨12.03%，盘 龙药业(002864)上涨5.35%，中恒集团(600252)上涨4.42%，亚宝药业(600351)上涨1.65%，以岭药业 (002603)上涨1.34%。中药ETF(159647)上涨0.50%，最新价报1.01元。 消息面上，多地流感活动呈上升趋势，中国疾控中心病毒病所国家 ...

数据显示，截至2025年11月28日，中证中药指数(930641)前十大权重股分别为云南白药(000538)、片仔 癀(600436)、同仁堂(600085)、东阿阿胶(000423)、华润三九(000999)、吉林敖东(000623)、白云山 (600332)、众生药业(002317)、以岭药业(002603)、达仁堂(600329)，前十大权重股合计占比54.79%。 中药ETF(159647)，场外联接(A：016891；C：016892；I：022881)。 中邮证券指出，基药目录调整工作有望继续推进，关注中药品种调增机会；中药材呈降价趋势毛利率有 望回升，看好社会库存出清方向以及创新驱动方向。 中药ETF紧密跟踪中证中药指数，中证中药指数选取涉及中药生产与销售等业务的上市公司证券作为样 本，以反映中药概念类上市公司的整体表现。 截至2025年12月1日 10:54，中证中药指数(930641)上涨0.79%，成分股粤万年青(301111)上涨8.41%，太 龙药业(600222)上涨5.22%，江中药业(600750)上涨3.73%，华神科技(000790)上涨3.31%，陇神戎发 (300534) ...

Core Viewpoint - The Chinese traditional medicine sector is experiencing a positive trend, with the Zhongzheng Traditional Chinese Medicine Index showing an increase, driven by rising flu cases and the performance of key stocks in the industry [1][2]. Group 1: Market Performance - As of November 24, 2025, the Zhongzheng Traditional Chinese Medicine Index (930641) rose by 0.68%, with a one-year dividend yield of 3.18% [1]. - Key component stocks such as Jiaying Pharmaceutical (002198) increased by 4.48%, Zhongsheng Pharmaceutical (002317) by 2.86%, and others also showed positive growth [1]. - The Zhongzheng Traditional Chinese Medicine ETF (159647) increased by 0.40%, with the latest price at 1 yuan [1]. Group 2: Flu Trends and Impact - The National Influenza Center reported that the ILI% in southern hospitals was 5.5%, up from 4.6% the previous week, and higher than the same period in 2022 and 2024 [1]. - Northern hospitals reported an ILI% of 6.1%, also higher than the previous week and exceeding levels from the last three years [1][2]. - The rising flu positivity rates in both southern and northern regions are attributed to lower immunity against the H3N2 strain and an earlier onset of the flu season this year [2]. Group 3: Industry Outlook - The flu season for 2025-2026 is expected to peak higher than the previous year, leading to increased demand for respiratory infection-related products [2]. - The traditional Chinese medicine sector is anticipated to face short-term performance pressure but is expected to benefit from policies related to centralized procurement and basic medicine, as well as innovation-driven growth [2]. - The top ten weighted stocks in the Zhongzheng Traditional Chinese Medicine Index account for 54.92% of the index, indicating a concentrated market structure [3].

Group 1 - The core viewpoint indicates a strong performance in the Traditional Chinese Medicine (TCM) sector, with the Zhongzheng TCM Index rising by 1.22% and individual stocks like Zhongsheng Pharmaceutical increasing by 9.98% [1] - The TCM ETF has shown a consistent upward trend, achieving an 8-day consecutive rise, with the latest price reported at 1.06 yuan [1] - The National Health Commission has projected a peak in influenza cases in China during mid-December to early January, which may positively impact the TCM market [1] Group 2 - CITIC Securities anticipates that the collection of traditional Chinese medicine will continue to expand, leading to increased brand concentration in the outpatient market [1] - The TCM industry is expected to reach a healthy inventory level by Q2 2025, following a period of destocking and sales efforts [1] - Continuous growth in R&D investment by TCM companies is highlighted as a key driver for future development, with a focus on innovative TCM contributing to stable growth [1]

Core Viewpoint - The Chinese medicine sector is experiencing a positive trend, with the Zhongzheng Traditional Chinese Medicine Index showing an increase, driven by policy benefits and the rapid modernization of classic formulas into contemporary medicine [1][2]. Group 1: Market Performance - As of November 12, 2025, the Zhongzheng Traditional Chinese Medicine Index (930641) rose by 0.57%, with notable increases in constituent stocks such as Zhongsheng Pharmaceutical (002317) up by 10.02% and Panlong Pharmaceutical (002864) up by 10.00% [1]. - The Chinese Medicine ETF (159647) also saw a rise of 0.29%, marking its sixth consecutive increase, with the latest price reported at 1.05 yuan [1]. Group 2: Industry Trends - There is a continuous release of policy benefits, leading to an accelerated layout of classic formulas by Chinese medicine companies, with products like Loquat Lung Cleansing Granules and Warming Meridian Decoction being rapidly transformed into modern formulations [1]. - Guojin Securities identifies the main investment opportunities in the pharmaceutical sector for 2025 as the innovation drug theme and the reversal of challenges in the left-side sector, emphasizing the potential of dual/multi-antibody drugs and addressing unmet clinical needs in chronic disease medications [1]. Group 3: Index Composition - The Zhongzheng Traditional Chinese Medicine Index includes companies involved in the production and sales of traditional Chinese medicine, with the top ten weighted stocks accounting for 54.92% of the index as of October 31, 2025 [2].